ストックスクリーナーアプリを入手
2.90
9.78%
-0.27
前日終値:
$3.17
開ける：
$3.12
24時間の取引高:
72,654
Relative Volume:
1.97
時価総額：
$101.19M
収益：
$1.88M
当期純損益:
$-15.57M
株価収益率:
-7.25
EPS:
-0.4
ネットキャッシュフロー:
$-50.09M
1週間 パフォーマンス:
-4.67%
1か月 パフォーマンス:
+68.24%
6か月 パフォーマンス:
+63.43%
1年 パフォーマンス:
+13.04%
1日の値動き範囲:
$2.755
$3.27
1週間の範囲:
$2.73
$3.44
52週間の値動き範囲:
$0.98
$3.44
Beyondspring Inc Stock (BYSI) Company Profile
名前
Beyondspring Inc
セクター
電話
646-528-4184
住所
100 CAMPUS DRIVE, WEST SIDE, 4TH FLOOR, FLORHAM PARK, NY
BYSI を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BYSI
Beyondspring Inc
|
2.84 | 101.19M | 1.88M | -15.57M | -50.09M | -0.40 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.06 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
511.35 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.59 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
541.00 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
257.52 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Beyondspring Inc Stock (BYSI) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-12-02 | ダウングレード | BofA Securities | Buy → Underperform |
| 2021-12-02 | ダウングレード | Jefferies | Buy → Hold |
| 2021-12-01 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2021-12-01 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2021-09-09 | 開始されました | Robert W. Baird | Outperform |
| 2021-08-04 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2021-04-05 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2021-01-11 | 開始されました | BofA Securities | Buy |
| 2020-12-29 | 開始されました | Evercore ISI | Outperform |
| 2020-02-07 | 開始されました | Jefferies | Buy |
| 2020-01-10 | 開始されました | Nomura | Buy |
| 2019-12-03 | 開始されました | William Blair | Outperform |
| 2019-07-10 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-04-30 | ダウングレード | Maxim Group | Buy → Hold |
| 2018-10-25 | 繰り返されました | Maxim Group | Buy |
すべてを表示
Beyondspring Inc (BYSI) 最新ニュース
BeyondSpring (NASDAQ:BYSI) Shares Up 30%Should You Buy? - MarketBeat
Big Cuts to U.S. Cancer Research May Create Historic Opening for Biotech Investors - Baystreet.ca
Exelixis Stock Surges 28% YTD: Should You Buy Now or Sell? - The Globe and Mail
BeyondSpring reports promising phase 2 NSCLC study results By Investing.com - Investing.com South Africa
BeyondSpring Presents Efficacy/Safety Data from a Phase 2 Study - GuruFocus
BeyondSpring Inc. Presents Efficacy/Safety Data from a Phase 2 Study of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progressing on First-Line Immune Checkpoint Inhibitors at 2025 ASCO Annual Meeting - marketscreener.com
BeyondSpring reports promising phase 2 NSCLC study results - Investing.com Australia
BeyondSpring (BYSI) Presents Promising Phase 2 Data in Lung Canc - GuruFocus
BeyondSpring (BYSI) Presents Promising Phase 2 Data in Lung Cancer Study | BYSI Stock News - GuruFocus
BeyondSpring Inc. Reports Promising Interim Phase 2 Data for Plinabulin in Metastatic NSCLC Showing 6.8 Months Median PFS and 78% Overall Survival Rate - Nasdaq
BeyondSpring Presents Efficacy/Safety Data from a Phase 2 - GlobeNewswire
BeyondSpring Presents Efficacy/Safety Data from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at 2025 ASCO Annual Meeting - TradingView
New Clinical Data: BeyondSpring's Triple Therapy Doubles Survival in Drug-Resistant Lung Cancer Patients - Stock Titan
BeyondSpring Announces Poster Presentation at 2025 ASCO Annual Meeting | BYSI Stock News - GuruFocus
BeyondSpring Announces Poster Presentation at 2025 ASCO Annual Meeting - GlobeNewswire
Monte Rosa Therapeutics to Participate in the Jefferies Global Healthcare Conference - The Manila Times
Neutropenia Drugs Market Revenue to Surpass USD 24.2 Billion by 2033 with 4.7% CAGR - openPR.com
Should You Buy, Hold or Sell OKTA Stock Before Q1 Earnings Release? - The Globe and Mail
BeyondSpring Reports Q1 2025 Financials and Clinical Progress - TipRanks
BeyondSpring (NASDAQ:BYSI) Posts Earnings Results - MarketBeat
Can BeyondSpring (NASDAQ:BYSI) Afford To Invest In Growth? - Yahoo Finance
Can Saudi AI Deals Boost AMD Over NVIDIA, and Is It a Buy? - The Globe and Mail
BeyondSpring Inc. (BYSI) Reports Q1 Loss of $0.08 - StreetInsider
BeyondSpring Reports First?Quarter 2025 Financial Results and Provides Corporate Update | BYSI Stock News - GuruFocus
BeyondSpring Inc. Reports Positive Early Results for Plinabulin in Metastatic Cancer and Updates on SEED Therapeutics' Progress - Nasdaq
BeyondSpring Reports First‑Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
BeyondSpring, Inc. Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm - ACCESS Newswire
Press Release Distribution & PR Platform - ACCESS Newswire
SEED Therapeutics Secures FDA Rare Pediatric and Orphan Drug Designations for ST-01156 - MSN
BeyondSpring (NASDAQ:BYSI) Shares Pass Below 50 Day Moving AverageTime to Sell? - MarketBeat
BeyondSpring stock hits 52-week low at $1.34 amid market challenges By Investing.com - Investing.com South Africa
BeyondSpring stock hits 52-week low at $1.34 amid market challenges - Investing.com India
BeyondSpring (NASDAQ:BYSI) Trading Down 3.8%Here's Why - MarketBeat
BeyondSpring’s 2024 Progress and Strategic Milestones - TipRanks
BeyondSpring stock hits 52-week low at $1.4 amid sharp decline By Investing.com - Investing.com South Africa
BeyondSpring stock hits 52-week low at $1.4 amid sharp decline - Investing.com
BeyondSpring Inc. (BYSI) reports earnings - Quartz
BeyondSpring Reports 2024 Year-End Financial Results and Highlights Key Clinical & Strategic Milestones - The Manila Times
BeyondSpring Files 2024 Annual Report on Form 10-K - GlobeNewswire
Beyondspring Inc (BYSI) 財務データ
収益
当期純利益
現金流量
EPS
0.66%
1.05%
大文字化:
|
ボリューム (24 時間):